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Abstract
Monoclonal and recombinant antibodies are ubiquitous tools in diagnostics, therapeutics, and biotechnology. However,
their biochemical properties lack optimal robustness, their bacterial production is not easy, and possibilities to create
multifunctional fusion proteins based on them are limited. Moreover, the binding affinities of antibodies towards their
antigens are suboptimal for many applications where they are commonly used. To address these issues we have made use
of the concept of creating high binding affinity based on multivalent target recognition via exploiting some of the best
features of immunoglobulins (Ig) and non-Ig-derived ligand-binding domains. We have constructed a small protein, named
Neffin, comprised of a 118 aa llama Ig heavy chain variable domain fragment (VHH) fused to a ligand-tailored 57 aa SH3
domain. Neffin could be readily produced in large amounts (.18 mg/L) in the cytoplasm of E. coli, and bound with
a subpicomolar affinity (Kd 0.54 pM) to its target, the HIV-1 Nef protein. When expressed in human cells Neffin could
potently inhibit Nef function. Similar VHH-SH3 fusion proteins could be targeted against many other proteins of interest and
could have widespread use in diverse medical and biotechnology applications where biochemical robustness and strong
binding affinity are required.
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Introduction
Specific recognition and strong binding to chosen target
molecules is the cornerstone of modern therapeutic and diagnostic
practices. Monoclonal antibody technology pioneered by Ko¨hler
and Milstein in the 1970’s revolutionized medical and other fields
of immunodiagnostic development [1], and currently accounts for
a significant portion of new drugs approved for treatment of major
human diseases, such as cancer and autoimmune disorders [2,3].
Subsequent progress in molecular biology has made it possible
to generate recombinant antibodies with rationally altered binding
properties and multifunctional fusion partners [4,5]. Recombinant
antibodies containing only the Fab fragment and single-chain
antibodies (scFv) comprised only of the variable domains of heavy
and light chains joined by a flexible linker peptide represent
simpler and smaller alternatives to complete immunoglobulins.
Fab and scFv proteins can be easily manipulated and often
produced in relatively large amounts in prokaryotic expression
systems. The possibility to select recombinant antibodies from
synthetic libraries and to optimize their properties by random and
targeted mutagenesis combined with powerful in vitro affinity
selection schemes have been fruitfully exploited in various
biotechnology applications. These approaches enable rational
targeting of antibody binding, including target epitopes that might
be poorly immunogenic, as well as overcoming the affinity ceiling
of monoclonal antibodies. While most natural antibodies have Kd
values in the range of 1028 to 10211 M [6,7], orders of magnitude
tighter binding has been reported for optimized recombinant
antibodies [8].
Despite these advantages, problems and limitations related to
recombinant antibodies exist, which have hindered their wide-
spread use. Due to the complex structure recombinant antibodies
show challenging biophysical properties, and are lacking the
robustness of ideal recombinant protein reagents [9,10,11,12].
Accordingly, recombinant antibodies have poor stability under
reducing conditions, such as the intracellular environment.
Moreover, their antigen recognition can be sensitive for context-
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specific steric effects, thus limiting the freedom to create
multifunctional fusion protein derivatives.
Therefore, several investigators have considered the use of non-
Ig proteins as sources (‘‘scaffold proteins’’) for novel high affinity
ligand binders via applying the same principles of sequence
diversification and affinity selection successfully applied in
recombinant antibody engineering. A growing number of proteins
and protein domains, with normal functions either related or
unrelated to protein interactions, have been established as suitable
backbones for engineering of artificial proteins with useful binding
specificities (for reviews, see [13,14,15]). Among the best validated
examples of these are affibodies based on the Z-domain of
staphylococcal protein A [16], monobodies based on the 10th
extracellular domain of human fibronectin III [17], and DARPins
(designed ankyrin repeat domains) comprised of an optimized
target binding interface built from four to six ankyrin repeat
modules with engineered binding properties [18].
Another attractive non-Ig scaffold is the SH3 domain [19,20],
representing a small (55–60 aa) protein module with a compact
beta-sandwich fold lacking disulfide bridges, which can be easily
expressed in large amounts and in soluble form in E. coli. By
randomizing the non-conserved flexible loops of SH3 domains
they have been successfully targeted for binding to diverse ligand
proteins with low nanomolar affinities [21,22,23].
An alternative approach to address the challenges related to the
biochemical properties of recombinant antibodies has been to
exploit the ability of certain immunoglobulin variable domains to
bind target antigens as independent monomeric units [24]. In
particular, camelids and sharks naturally produce a class of
antibodies comprised only of the heavy chain [25]. Variable
domain fragments of camelid antibodies, termed VHH domains,
nanobodies, or single-domain antibodies (sdAb), can bind to their
cognate antigens with affinities comparable to regular antibodies,
but due to their simpler architecture have advantageous bio-
physical properties (solubility, stability) [26,27,28], and offer
attractive opportunities for further molecular design [29]. Re-
markably, the typical length of an sdAb is only 120 amino acid
residues, thus representing the most minimalistic form of an
antibody.
Enhanced affinity in natural protein interactions is often
achieved via combined use of multiple binding domains. Neri
and colleagues have successfully exploited this principle in
antibody engineering by creating heterodimeric proteins (dubbed
CRAb for chelating recombinant antibody) built of two linker-
connected scFv’s binding to adjacent non-overlapping epitopes in
a common target antigen [30]. An impressive strength of binding
(Kd in low picomolar range) was obtained as a result of more than
a 100-fold increase in affinity compared to either one of its scFv
components.
However, it is evident that the problems related to antibody
structure and biochemistry will increase rather than decrease upon
fusing two scFv molecules together. Therefore, it would be an
attractive idea to use heterologous (i.e. non-Ig-derived) ligand
binding proteins as co-operating components of multi-domain
constructs designed for high affinity target recognition. Indeed,
increase in affinity and specificity by the formation of multivalent
interactions is a well-known concept in modular protein interac-
tions (see [31,32]). Examples of this approach in protein
engineering are the ‘‘affinity clamp’’ proteins constructed by
Koide and colleagues based on optimized fibronectin domains
fused with PDZ domains [33], and the ‘‘avimers’’ construted by
Silverman and colleagues based on multimers of cell-surface
receptor-derived A-domains [34].
In the present study we have created a promising new multi-
domain protein with strongly cooperative target binding properties
by combining some of the best concepts in antibody engineering
and in non-Ig scaffold design. We have generated a fusion protein
comprised of an sdAb fragment derived from a llama immunized
against the HIV-1 pathogenicity factor Nef with a synthetic
library-derived SH3 domain optimized for binding to Nef. The
resulting small (,200 residues) polypeptide showed greatly
enhanced binding to Nef compared to either one of its individual
components alone, resulting in a subpicomolar binding affinity.
This fusion protein, designated as ‘Neffin’, showed favorable
biochemical and functional properties, could be easily produced in
high amounts in E. coli, and acted as a potent intracellular
inhibitor of Nef function in human cells.
Results
Construction of Neffin
Bivalent target recognition is an attractive concept for
generating high affinity binding polypeptides for therapeutic and
diagnostic applications. To exploit this strategy but to avoid
problems related to poor expression, stability and solubility we
chose to create a chimeric polypeptide comprised of a minimalistic
antigen-binding Ig fragment fused to a small non-Ig protein-
binding domain. To this end we combined a 118 amino acid
llama-derived single domain Ig heavy chain variable domain
fragment (VHH) with a 57 amino acid SH3 domain derived from
the human Hck tyrosine kinase.
The VHH domain (termed sdAb19) was cloned from a llama
immunized against the HIV-1 pathogenicity factor Nef, and has
shown to be able to inhibit intracellular functions of Nef [35].
Likewise, the SH3 domain (SH3-B6) used here has been optimized
for binding to HIV-1 Nef by manipulation of the amino acid
sequence in the specificity-determining RT-loop region of Hck
SH3 [22], and has been shown to be able to inhibit Nef as such
[36], or as an improved fusion protein including a Nef-binding
fragment from human CD4 [37]. We dubbed the resulting anti-
Nef VHH-SH3 domain chimera Neffin.
Since the exact target site in Nef is only known for SH3-B6 [38],
but not for sdAb19, we first analyzed SH3 and sdAb19 binding to
Nef by size-exclusion chromatography to ask if both protein
domains could bind simultaneously to the surface of Nef. These
experiments were performed using the core domain of Nef
comprising residues 41–206 (Fig. 1A). Both Nef and sdAb19 run at
elution volumes of their expected sizes indicating a monomeric
dispersion of the two proteins. Addition of sdAb19 to Nef led to
a marked increase in protein size displayed by an earlier elution
volume, which corresponded to the tight complex formation
between these proteins. Addition of SH3-B6 to Nef and sdAb19
furthermore increased the size of the protein eluate to an apparent
size of about 44 kDa. This elution profile indicated the tripartite
formation of the Nef–sdAb19–SH3-B6 complex (Fig. 1A). These
results confirmed that binding of the SH3 domain to the PxxPxR
motif in Nef and binding of sdAb19 to Nef is complementary and
not mutually exclusive.
Having confirmed that SH3-B6 could bind to Nef simulta-
neously with sdAb19 we next tested a panel of Gly-Ser-containing
linkers of different lengths introduced between SH3-B6 and
sdAb19 to generate a fusion protein that would enable synergistic
binding to Nef. Nine different Neffin constructs were generated in
which sdAb19 was connected to SH3-B6 via linkers ranging from
4 to 48 aa in length (see Fig. 1B). Due to the modular nature of the
SH3 fold it is relatively insensitive to the context where it is placed,
and tolerates well fusion of heterologous sequences both at its N-
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and C-termini. Instead, the antigen binding capacity of single-
domain antibody fragments might be compromised by foreign
material appended to the N-terminus. Therefore, in all cases the
Neffins were designed such that the sdAb19 was located N-
terminally in the fusion protein and linked from its C-terminus to
the SH3 domains.
Despite the large variation in the length of the linkers tested, our
preliminary studies based on pull-down experiments from Nef and
Neffin transfected cell lysates, and affinity measurements with
surface plasmon resonance did not reveal noticeable differences in
the Nef-binding capacity of these Neffin variants, and all Neffin
variants seemed to have greatly increased Nef binding potential
compared to sdAb19 (data not shown). Therefore, we chose the
seven-residue linker AAGGSGG construct for all further studies.
To facilitate Neffin purification and detection, a C-terminal Myc-
hexahistidine tail was added to this Neffin construct.
Biochemical Properties of Neffins
Due to small size and simple architecture of Neffin we hoped
that its biochemical properties would be robust enough to enable
large-scale production in soluble and functional form in the
cytoplasm of E. coli without a need for targeting to periplasmic
expression. When using a regular T7-derived bacterial vector large
amounts of Neffin could be expressed in the cytoplasm of E. coli
cells in regular flask cultures, and easily purified by standard
nickel-resin affinity chromatography. With minimal optimization
of the experimental conditions .18 mg/L of Neffin could be
readily obtained (Fig. 2A). Of note, the amount of Neffin
recovered from E. coli was consistently at least twice higher than
the yields of the sdAb19 fragment expressed individually. No
significant differences in the expression levels were observed when
the BL21(DE3) E. coli cells were compared with thioredoxin
reductase (trxB) and glutathione reductase (gor) deficient Origa-
mi(DE3) host cells (data not shown). Also, the proportion of
functional protein was equally high in both cases, as similar
amount of Neffins purified from BL21(DE3) or from Origa-
mi(DE3) cells could be re-captured to glutathione-S-sepharose
beads coated with GST-Nef (Fig. 2B). Thus, we conclude that
correct folding or disulphide bond formation did not limit high
level cytoplasmic expression of functional Neffin proteins.
In summary, the VHH-SH3 double domain architecture
seemed to be very well suited for bacterial expression, and the
inclusion of the well-folding SH3 domain improved rather than
compromised the favorable properties of the llama VHH
fragment.
Affinity for Nef
To further examine the Nef-binding properties of Neffin, we
immobilized GST-Nef onto a Biacore biosensor chip, and
analyzed the association of different concentrations of sdAb19 or
Neffins by surface plasmon resonance (Fig. 3A). When these curves
were fitted to Langmuir 1:1 model we found that both sdAb19 and
Neffin bound to Nef with impressive on-rates (ka of
1.416106 M21s21 and 1.516106 M21s21, respectively). The
value recorded for sdAb19 is somewhat higher than published
originally by Bouchet et al. [35]. We therefore carefully double-
Figure 1. Design of a VHH-SH3 fusion protein (Neffin) targeted against HIV-1 Nef. (A) Size exclusion chromatography analysis confirming
the expected molecular sizes for the monomeric Nef, sdAb19, and SH3-B6 proteins and for the dimeric sdAb19/Nef and the trimeric sdAb19/Nef/SH3-
B6 complexes. (B) Domain organization of Neffin and the amino acid sequences of the different linkers tested for joining of sdAb19 and SH3-B6.
doi:10.1371/journal.pone.0040331.g001
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checked the concentration of the sdAb19 and Neffin-B6 prepara-
tions, generated independent new protein preparations, and
repeated the measurements several times. The results were highly
consistent leading us to conclude that sdAb19 binds to Nef with
a remarkably rapid association rate, which is not significantly
increased by fusion with SH3-B6.
It could be expected that the on-rate of binding cannot be
increased by creating bivalent fusion proteins, and the potential
gain of function would be provided by increased stability of
binding. Indeed, evidence of slower dissociation of the Nef–Neffin
complex as compared to the Nef–sdAb19 complex could be
observed in exteneded Biacore runs with dissociation times much
longer than those used in Fig. 3A (data not shown). However, the
off-rate of sdAb19 was already slow (,1024 s21), and analysis of
slow dissociation rates using Biacore is challenging [39,40,41]. To
generate an experimental system suitable for examining the
stability of the Nef–Neffin complex we set up an ‘‘ELISA-like’’
assay shown in Fig 3B.
In this assay microtiter plates were coated with the Nef
protein, followed by incubation of sdAb19 or Neffin protein.
After washing of the plates, an excess of soluble Nef protein was
added to the wells to capture sdAb19/Neffin that dissociated
from the immobilized Nef protein. At various times up to 48
hours the amount of sdAb19/Neffin that remained bound to the
immobilized Nef was determined using a labeled antibody
against the hexahistidine tag of sdAb19/Neffin. As shown in
Fig. 3B the rate of dissociation from Nef was dramatically
slower for Neffin compared to sdAb19. Based on these data
dissociation rates of 2.1761025 s21 and 8.1261027 s21, re-
spectively, were calculated.
When combining the association rates determined by Biacore
with the dissociation rates determined by the off-rate ELISA,
dissociation constants corresponding to the overall binding
affinities could be calculated, Kd= 1.5610
211 M (15 pM, sdAb19)
and 5.4610213 M (0.54 pM, Neffin). Thus, based on these
analyses, we conclude that the VHH-SH3 fusion strategy resulted
in synergistic bivalent binding of extreme affinity, and that Neffin
bound to Nef 28-fold and more than 1000-fold better than its
components sdAb19 and SH3-B6 (Kd = 12.3 nM; [38], see also
Figure S2).
Since Biacore measurements can be sensitive to the surface
density of the immobilized ligand it was important to examine if
the tendency of GST to dimerize could have influenced our
Biacore measurements based on GST-Nef immobilized onto the
biosensor chips via an anti-GST antibody Therefore, we produced
Nef as a fusion protein with the monomeric maltose binding
protein (MBP), and compared binding of Neffin to GST-Nef and
MBP-Nef covalently coupled directly onto Biacore chips. These
experiments revealed identical sensorgrams (Figure S1), thus ruling
out any significant contribution of GST dimerization to the
recorded Neffin binding kinetics. We also tested MBP-Nef instead
of GST-Nef in the off-rate ELISA, and again observed virtually
identical results (data not shown).
Figure 2. Bacterial expression of Neffin. (A) sdAb19 and Neffin were expressed in the cytoplasm of E. coli Origami cells in 50 ml flask cultures
and captured to 0.2 ml of nickel-agarose resin. A Coomassie blue–stained gel containing 10 ml aliquots of the first three 0.5 ml fractions (F1–F3) of
sdAb19 and Neffin eluated from the resin is shown. (B) Comparison of Nef-binding capacity of Neffin produced in BL21 or Origami cells. 10 mg (lanes
1 and 3) or 5 mg (lanes 2 and 4) of BL21- or Origami-derived Neffin were incubated with 10 mg GST-Nef or plain GST. Equal fraction of proteins
captured to glutathione-resin well as input material were analyzed by SDS-PAGE and Coomassie blue–staining.
doi:10.1371/journal.pone.0040331.g002
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Neffin can Efficiently Bind and Inhibit Nef in Human Cells
The favorable biochemical properties of recombinant Neffin as
well as the earlier studies on mammalian cell expression of SH3-
B6 and sdAb19 [35,36] suggested that the extreme Nef-binding
capacity of Neffin might also be exploited in intracellular targeting
and inhibition of Nef in human cells.
To this end, we transfected human 293 T cells with sdAb19 or
Neffin expression constructs together with a vector expressing
GFP-tagged Nef (Nef-GFP), and examined their ability to associate
with Nef in these cells. In addition to the SH3-B6 containing
Neffin (Neffin-B6 in Fig. 4), we included also another Neffin
variant, namely Neffin-C1 (containing another Hck-derived Nef-
targeted SH3 domain, SH3-C1, [22]) to this experiment. Forty-
eight hours after transfection, the cells were lysed and Nef-GFP
was immunoprecipitated, and the proteins in these precipitates
were analyzed by SDS-PAGE and Western blotting. As shown in
Fig. 4, when equal amounts of Nef-GFP together with sdAb19 or
a Neffin were transfected into cells (see blotting of the total lysates),
Neffins were very efficiently co-precipitated with Nef-GFP. While
sdAb19 readily associated with Nef-GFP, the amount of co-
precipitated sdAb19 was much weaker compared to Neffin-B6 and
Neffin-C1. Thus, we concluded that the increased affinity of Neffin
observed in vitro also translated in an enhanced association with
Nef in human cells. Interestingly, for reasons that remain to be
Figure 3. Estimation of binding affinity and kinetics for the Nef-Neffin interaction. (A) Biacore sensorgrams used for calculating the on-
rates 1.416106 M21s21 and 1.516106 M21s21 for binding of sdAb19 and Neffin to Nef. The off-rates for both interaction were too slow to be reliably
estimated by this method. (B). Competitive ELISA for estimation of the off-rates of 2.1761025 s21 and 8.1261027 s21for binding of sdAb19 and
Neffin to Nef.
doi:10.1371/journal.pone.0040331.g003
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explored the gain in Neffin function provided by the SH3 moiety
appeared to be even greater than found in using purified proteins
in vitro.
To study functional inhibition of Nef we chose to examine the
capacity of sdAb19 and Neffins to suppress Nef-mediated
enhancement of the catalytic activity of the Hck tyrosine kinase.
This activation is caused by binding of Nef to the SH3 domain of
Hck that is involved in keeping Hck in an enzymatically inactive
conformation [42]. The activation of Hck was monitored using
a phosphospecific antibody against the activation loop of Hck,
which becomes autophosphorylated upon Hck activation. As
shown in Fig. 5, Neffin-B6 and Neffin-C1 reduced the level of
phospho-Hck to the baseline level seen in cells lacking Nef.
Instead, in sdAb19-transfected cells Hck autokinase activity was
induced as highly as in cells expressing only Nef with Hck. In
addition to its lower capacity to associate with Nef in the
transfected cells (Fig. 4), the failure of sdAb19 to suppress Hck
activity may also be due to its mode of Nef binding, which does not
lead to masking of the SH3 binding surface of Nef. Based on these
data we concluded that Neffins could act as potent intracellular
inhibitors of Nef.
Discussion
In this study we describe a novel bivalent ligand binding protein
constructed by fusion of a single-domain Ig heavy chain variable
domain fragment with an optimized SH3 domain. The resulting
fusion protein, named Neffin, remains very small in size
(,20 kDa) and could be readily produced in large amounts as
a soluble and functional protein in E. coli. Yet, the binding of
Neffin to its target protein, the HIV-1 pathogenicity factor Nef,
showed very high affinity (estimated to be 0.54 pM) that can rarely
be observed for natural or engineered antibodies, or the different
types of recombinant ligand targeting proteins described so far.
The VHH-SH3 design therefore provides an interesting new
approach for targeting of any protein of therapeutic or diagnostic
importance. By immunizing camelids or via the use of synthetic
gene libraries VHH fragments specific for a plethora other ligands
can be generated. Based on earlier published work [28,43,44] as
well as our own studies on unrelated VHH fragments (unpublished
results), the robust and useful biophysical properties of sdAb19 are
not a specific feature of this particular molecule, but instead
appear to be shared by most VHH fragments of camelid origin.
Likewise, ligand-tailored SH3 domains can be readily engineered
for recognition of divergent target proteins of interest, including
proteins that serve as ligands for natural SH3 domains as well as
proteins that do not [21,23]. To expedite finding of SH3 and
VHH domains capable of co-operative bivalent binding rational
screening approaches could be designed, for example by mixing
one of the domains in excess in soluble form with the display
library.
The published work on artificial, ligand-specific SH3 domains
has relied on modification of SH3 domains derived from the Src-
family tyrosine kinases [21,22,23,45]. However, our recent
unpublished studies on systematic testing of unrelated SH3
Figure 4. Efficient association of Neffin and Nef expressed in human cells. GFP-tagged Nef was co-expressed in 293 T cells together with
sdAb19, Neffin-B6 or Neffin-C1, and the amount of sdAb19, Neffin-B6, or Neffin-C1 associated with anti-GFP immunocomplexes was determined by
Western blotting (top panel). Even precipitation of GFP-Nef as well as equal expression of Nef, sdAb19, Neffin-B6, and Neffin-C1 in the lysates of the
transfected cell cultures is shown as indicated. Blotting of the lysates with an antibody for the endogenous a-tubulin is used as a loading control.
(bottom panel).
doi:10.1371/journal.pone.0040331.g004
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domains from divergent protein families have revealed even more
suitable SH3 scaffolds for this purpose. Thus, due to its small size,
efficient folding, and tolerance of extensive manipulation of its
loop regions, the SH3 domain is an excellent scaffold for
generating non-Ig-derived ligand-binding proteins for a variety
of biotechnological and medical applications.
The concept of generating high binding affinity using multiva-
lent recombinant proteins is not new, but has so far not been
widely exploited. However, the simple design and robust
properties of Neffin described here provide a strong case of the
utility of this approach. The reasons for the rarity of existing
applications of the multivalent binder concept are not clear, but
are likely related at least in part to poor expression and solubility of
many potentially useful protein binding domain combinations. By
contrast, more than 18 mg/L of Neffin could be readily produced
from regular flask cultures of E. coli, which is 10-times more than
what is generally considered as a good yield for single-chain (scFv)
or Fab antibody fragments. Moreover, this amount could be
produced using cytoplasmic expression, thus circumventing the
need for periplasmic targeting, thereby further simplifying and
increasing the robustness of recombinant Neffin production.
Because of these advantages the VHH-SH3 design has the
potential to become a widely used approach to generate high-
affinity recombinant ligand-binding proteins in a manner com-
patible with the practical and technical requirements of actual
biotechnology applications.
The extreme binding affinity of the Neffin-Nef interaction can
be traced to the strong Nef-binding capacities of its VHH and SH3
components individually. However, considering the remarkable
ability for these two small domains to functionally co-operate,
binding affinities superior to that of most antibodies could be
achieved using VHH and SH3 components having more modest
individual binding capacities compared to sdAb19 and SH3-B6.
The affinity (Kd 0.54 pM) measured for the Nef-Neffin interaction
is indeed remarkable. This binding is much stronger than found in
natural antibody-antigen interactions or in the majority of
bioengineered interactions. Due to the challenge in accurately
determining very slow dissociation rates, however, the overall
affinity could be somewhat overestimated (but also underesti-
mated). In this regard, it is possible that our ELISA-like off-rate
assay based on surfaces immobilized with Nef might support more
stable Neffin binding than what occurs in solution. We have also
performed isothermal titration calorimetry (ITC) experiments to
study the Nef-Neffin interaction in solution (data not shown).
However, also this technique is poorly suited for determination of
dissociation constants in the subnanomolar affinity range, and
while the ITC studies did confirm the Nef-Neffin interaction to be
of a very high affinity, no absolute value for the dissociation
constant could be determined. In any case, it is clear that the
VHH-SH3 design enables synergistic binding leading to small
(,20 kDa) proteins with binding capacity superior to that of
typical antibodies.
Targeting the function of the viral pathogenicity factor Nef with
the Neffin protein could have therapeutic applications in the
management of HIV-1 infection. The ongoing progress in
molecular medicine and research on gene therapy might allow
efficient delivery of Neffin into the target cells of HIV-1. Blocking
the intracellular function of Nef would be expected to have several
beneficial effects, and could provide therapeutic synergy with the
existing antiretroviral drugs. In this study we show evidence of
inhibition of one of the intracellular functions of Nef, namely
suppression of Nef-induced Hck tyrosine kinase activity. However,
in another recent study we have extensively characterized the
capacity of Neffin to inhibit a large panel of known cellular
functions of Nef, and found that all these Nef-induced changes in
the host cell behavior could be abrogated by Neffin co-expression
(Bouchet et al., submitted).
Figure 5. Potent inhibition of Nef-induced Hck activation by Neffin. An expression vector for the tyrosine kinase Hck was co-transfected to
293 T cell with an empty control vector (left lane) or with an expression vector for HIV-1 Nef (other lanes). In Nef-transfected cells a vector for sdAb19,
Neffin-B6, or Neffin-C1 was included as indicated. Lysates of these cells were subjected to Hck-pulldown and the amount of activated (pHck; top
panel) and total Hck (second panel) these precipitates determined by Western blotting. Corresponding amounts of Nef, sdAb19, Neffin-B6, and
Neffin-C1 in the total lysates of the transfected cells was confirmed (third and bottom panels). A quantitation of relative Hck activation in the
transfected cells normalized to the total amount of precipitated Hck is shown on the right, where the amount of autophosphorylated Hck in cells
lacking Nef is set to one, and the phospho-Hck blotting signals from the other cells are graphed relative to this.
doi:10.1371/journal.pone.0040331.g005
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Similar to the current development and use of antibodies and
other affinity reagents for therapeutic purposes, the most obvious
applications of ligand-specific VHH-SH3 proteins would be in
blocking of extracellular targets involved in the pathogenesis of
diseases like cancer and autoimmunity. However, the ease and
versatility of generation and production of VHH-SH3 chimeras
suggest that this approach could also be exploited to replace
antibodies in a variety of other in vitro and in vivo practices in
medicine as well as in industrial and biotechnology applications.
Methods
Bacterial Fusion Proteins
The cloning of GST-NefR71 and MBP-NefR71 has been
described elsewhere [46]. GST-Nef, GST, MBP-Nef, and MBP
were produced by introducing a corresponding plasmid vector into
BL-21 strain of E.coli bacteria. The bacteria were grown to an
optical density at 600 nm (OD600) of 0.6–0.8 (37uC, 250 rpm)
followed by induction of protein expression with 1000 mM IPTG
(isopropyl b-D-1-thiogalactopyranoside). Expression and purifica-
tion of the GST proteins were carried out by standard methods as
recommended by the supplier of the pGEX vectors and
glutathione resin (Pharmacia). Expression and purification of the
MBP proteins were carried out by standard methods as
recommended by the supplier of the pMALC26 vectors
(Novagen) and amylose agarose resin (Pharmacia).
In order to clone Neffin-B6 or sdAb19 into pET 12a bacterial
expression vector, a DNA fragment encoding the Neffin-B6 or
sdAb19 as well as the Myc and His-tag encoding sequences was
amplified by PCRusing the Fusion polymerase enzyme (Finnzymes)
and primers containing the NdeI and BamHI site. This fragment
was inserted into the corresponding sites in pET 12a vector, and
used for expression of His-tagged fusion proteins without theOmpT
leader sequence in theN-terminus of the fusion protein inOrigami 2
E.coli. The bacteria were grown to an optical density at 600 nm
(OD600) of 0.40 (37uC, 250 rpm) followed by induction of protein
expression with 50 mM IPTG (isopropyl b-D-1-thiogalactopyrano-
side) for 21 hours (27uC, 220 rpm). Purification of the His-tagged
fusion proteins were carried out by standard methods as recom-
mended by the supplier of the Ni-NTA resin (Qiagen). Concentra-
tion measurements were performed using the BioRad (Lowry)
method using bovine serum albumin as a standard.
GST Pulldown
10 ug of purified GST-proteins (GST-R71 Nef or GST) were
incubated with 10 ug or 5 ug of purified His-tagged sdAb19 or
Neffin-B6 protein for 1 hour at +4uC in ELB pull down buffer
(150 mM NaCl; 50 mM HEPES [N-2-hydroxyethylpiperazine-
N9-2-ethanesulfonic acid], pH 7.4; 0.1% Igepal; 5 mM EDTA
[ethylenediaminetetraacetic acid] and protease inhibitors (Roche)).
Prewashed magnetic GST-sepharose beads (Promega, Madi-
son,WI) were added to protein complexes and incubated for
1.5 h at +4uC. Pulldown samples were washed 3 times with the
ELB buffer followed by SDS-PAGE and Coomassie protein
analysis.
Plasmids Used in Cell Transfection
Cloning of (WT) NefSF2 into pEGFP-N1 vector (Nef.GFP) and
sdAb19 into pcDNA3 vector has been described previously
[35,47]. Fusion proteins Neffin-B6 and Neffin-C1 were con-
structed by transferring an RRT-SH3 (B6 or C1) fragment from
corresponding expression vectors into NotI site of sdAb19-
pcDNA3 vector. Shortly, DNA fragment encoding the RRT-
SH3 fragment was amplified by PCR using primers containing the
NotI and EagI sites and nuleotides containing various linker
peptides (see Fig. 1B), followed by insertion of this fragment into
NotI site of sdAb19-pcDNA3 vector.
For Hck expression, an insert encoding wt human p61Hck was
cloned into pEBB expression vector containing a C-terminal biotin
acceptor domain (pp). The insert was PCR amplified from image
clone 4855747 (GenBank: BC014435.1) plasmid template using
primers containing the BglII and KpnI sites.The amplified insert
was digested with indicated restriction enzymes and ligated into
BamHI and KpnI restricted pEBB-pp plasmid.
Cell Culture and Transfection
293 T human embryonic kidney cells were routinely cultured in
a humidified 5% CO2 atmosphere at 37uC in Dulbecco modified
Eagle medium (DMEM), supplemented with 10% (wt/vol) fetal
calf serum (FCS), 1% L-glutamine and 1% penicillin-streptomy-
cin. 293 T cells were transiently transfected using Fugene 6
transfection reagent according to the manufacturer’s instructions.
Antibodies and Reagents
The following antibodies were used for experiments: Sheep
polyclonal antibody to GST-Nef was a kind gift from Mark Harris
(Leeds University, UK). Rabbit polyclonal antibodies against
hexahistidine tag and Hck were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). The rabbit polyclonal antibody
to pHck (ab5203) was from Abcam (Fremont, CA) and rabbit
polyclonal antibody to GFP (598) was from Nordic Biosite (Ta¨by,
Sweden). Mouse monoclonal anti-polyHistidine antibody (H1029,
clone HIS-1), mouse monoclonal anti-a-Tubulin antibody (T6199)
and goat polyclonal Anti-Mouse IgG HRP conjugate were from
Sigma Aldrich (St. Louis, MO). The secondary IR-conjugated
antibodies were from LI-COR Biosciences. Fugene 6 transfection
reagent was purchased from Roche Diagnostics Corporation
(Indianapolis, IN).
Western Blotting
Tissue culture cells were lysed in KEB lysis buffer (137 mM
NaCl, 50 mM Tris HCl [pH 8], 2 mM EDTA, 0.5% Igepal and
protease inhibitors (Roche)) and subjected to immunoprecipitation
using rabbit anti-GFP serum as described [47]. For determination
of phosphorylation status of Hck, cells were lysed to in vitro kinase
assay (IVKA) lysis buffer (150 mM NaCl; 50 mM HEPES,
pH 7.4; 1% Triton X-100; 10% glycerol; 5 mM EDTA;
7.5 mM MgCl2 and protease and phosphatase inhibitors (Roche)).
Forty to sixty micrograms of total proteins were analyzed by 12–
15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and blotted according to standard protocols. Protein
detection was performed following incubation with appropriate
first and IR-conjugated secondary antibodies followed by de-
tection with Odyssey imager (LI-COR Biosciences) according to
the manufacturer’s instructions.
Immunoprecipitation and Pulldown
For detection of association between Nef-GFP and sdAb19 or
Neffins, cell extracts from transfected 293 T cells were incubated
with anti-GFP rabbit polyclonal antibody for 2 hours at +4uC.
Immunocomplexes were coupled to protein A Sepharose beads for
an additional 2 hour at +4uC and washed 3 times with the lysis
buffer. For detection of pHck, cell extracts from Hck-pp-
transfected 293 T cells were incubated with streptavidin beads
(Invitrogen) for 2 hours at +4uC and washed 3 times with the lysis
buffer. Immunoprecipitations and pulldown samples were sub-
jected to SDS-PAGE and Western blotting analysis.
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Size Exclusion Chromatography
Analytical gel filtrations of recombinant NefNL4–3, SH3-B6,
sdAb19, and complexes thereof were performed using a multicom-
ponent Waters 626 LC system (Waters, MA) equipped with
a Superdex S75 (10/30) column (Amersham Biosciences).
Typically, 100 ml of a 150 mg/ml protein solution was loaded
onto the column that was equilibrated in 10 mM Tris/HCl
(pH 9.0), 100 mM NaCl buffer prior to injection of the protein
samples. Gel filtrations were run at a flow rate of 0.5 ml per
minute in 10 mM Tris/HCl (pH 9.0), 100 mM NaCl onto the
S75 column at 4uC. The optical density was monitored at
a wavelength of 280 nm over the time course of the experiment.
Gel filtration experiments were performed repeated times.
Surface Plasmon Resonance
The affinities of sdAb19 and Neffin towards GST-Nef were
analyzed by surface plasmon resonance in the Biacore 2000
biosensor instrumentation (GE Healthcare). First, flow cells of
a CM5 biosensor chip were covalently coated with anti-GST
antibody using the protocol provided in GST capture kit (GE
Healthcare). In the beginning of each cycle, GST and GST-Nef at
10 mg/ml were captured on individual flow cells with a contact
time of 4 min and flow rate of 5 ml/min. The captured GST and
GST-Nef repeatedly gave an increase of 800–1000 resonance units
(RU) in baseline signal. The binding of various concentrations of
sdAb19 and Neffin ranging between 3.125–100 nM were analyzed
with a 2 min contact time and a subsequent 15 min dissociation
phase at a flow rate of 50 ml/min. At the end of each cycle the
surface was regenerated with 1 min pulse of 10 mM Glycine
(pH 1.7). The analytes were diluted in PBS running buffer which
was supplemented with 0.0005% p20. For analyte concentrations
of 6.25 nM the dissociation phase was also separately recorded for
a period of 2 h.
The data were evaluated by subtracting sensorgrams obtained
from GST-coated flow cells from those obtained with GST-Nef.
The subtracted sensorgrams were fitted to a Langmuir model
assuming 1:1 binding using BiaEvaluation Software 3.1 (GE
Healthcare).
Off-rate ELISA
Off-rate ELISA was performed in 96-well MaxisorpTM micro-
titer plates (Nunc, Langenselbold, Germany) coated over night at
4uC with 100 ml of MBP-Nef antigen (5 mg/ml in PBS). The wells
were washed 36with PBS-0.05% Tween20 and blocked with 5%
skimmed milk powder in PBS for 2 h at RT. Appropriate dilutions
of soluble binders were prepared in 26YT and incubated with the
coated antigen for 1 h at RT followed by washes 56with PBS-
0.05% Tween20 to remove unbound binders. At this starting point
(0 h), 100% of the binders were in complex with the antigen and
no free binder existed. Dissociation kinetics of the binder-antigen
complex was then monitored as a function of time using MBP-Nef
as a specific capture antigen to inhibit reassociation of the
dissociated binders, whereas MBP served as an irrelevant control
antigen. Specifically, three parallel wells were incubated in the
presence of an excess of MBP-Nef or MBP (100 ml of 300 nM
antigen in PBS) for diverse periods of time (0–48 h) followed by
washes 56with PBS-0.05% Tween20 to remove dissociated
binders. Functionality of the capture and control antigens was
controlled by coincubation of the binders with the antigens prior
to exposure to MBP-Nef-coated wells. The detection was
performed with mouse monoclonal anti-His-HRP antibody, which
recognizes the C-terminal His-tag of the binders, and TMB (3,39
5,59-tetramethylbenzidine) substrate. The staining reaction was
stopped with 1 M sulfuric acid and absorbance measured at
450 nm using Multiskan Ascent ELISA-reader (Thermo Fisher
Scientific). The mean absorbance values of triplicate samples were
normalized relative to the control. ( = 1).
Under first-order conditions, the kinetic dissociation constant
kd is directly related to the half-life of the bimolecular complex
(t1/2) in irreversible dissociation conditions through the equation:
t1/2 =2ln 0.5/kd, establishing an intuitive and direct relation
between kd and life-time of the complex [48]. Consequently,
normalized mean absorbances, reflecting the proportion of
bound binder at a given point of time, were used for calculation
of kd through the following equation: kd =2ln (Normalized
absorbance)/t.
Supporting Information
Figure S1 Surface plasmon resonance analysis to com-
pare binding kinetics of Neffin to immobilized GST-Nef
and MBP-Nef proteins. Nef fusion proteins were covalently
coupled directly onto CM5 biosensor chips (GE Healthare) and
100 nM of Neffin was injected as an analyte. The maximal
binding signals are indicative of the amount of functional MBP-
Nef and GST-Nef proteins immobilized, whereas the matching
shapes of the sensorgrams indicate very similar binding kinetics in
both cases. Similar to the data in Fig. 3A the off-rates were too
slow to be meaningfully determined, while the on-rates matching
well with data in Fig. 3A were obtained.
(TIF)
Figure S2 Surface plasmon resonance analysis of the
individual Nef binding capacity of SH3-B6. SH3-B6 was
expressed as a His-tagged MBP-fusion protein and immobilized
onto an NTA chip. Different concentrations of GST-Nef were
then injected as indicated. The association and dissociation rate
constants were obtained by fitting the obtained sensorgrams to
a Langmuir global fit model assuming 1:1 binding.
(TIF)
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